Overview

• The UK’s MHRA has updated its Yellow Card Scheme to accept reports of AI scribe inaccuracies and is urging GPs to flag suspected hallucinations or fabrications.
• Australia’s TGA has signaled that many AI scribes meet the definition of medical devices, requiring pre-market approval and inclusion in the ARTG under a pending regulatory review.
• Nearly one in four Australian GPs uses digital scribes and UK uptake is growing, even as formal oversight and clinical training on these tools remain limited.
• Experts insist that patients must be informed each time AI scribes are used and review generated notes, with some clinicians deleting transcripts after consultation to protect privacy.
• Alarm over hallucinated or erroneous entries, such as false disease flags leading to needless screenings, has prompted calls for rigorous studies on AI scribe safety, bias and long-term effectiveness.